Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Clinical Laboratory Correlates: AML and p27kip1

Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia

Leukemia volume 14, pages 28–33 (2000)Cite this article

Abstract

There are few molecular biologic determinants that are prognostic for patients with acute myeloid leukemia (AML). Hence, we examined whether cellular levels of the cyclin-dependent kinase inhibitor p27Kip1 in acute myeloid leukemia could be used to predict clinical outcome in AML. Using immunoblot analysis, levels of p27 were assessed in blast cells from 72 AML patients who were registered and treated by the identical chemotherapy protocol. AML cases were classified into three groups on the basis of the percentage of the expression level of p27 compared to a control cell line. AML cases exhibiting p27 expression at low, moderate, and high levels were 43, 9, and 20 cases, respectively. No significant differences in the rates of complete remission (CR) were observed among the three groups. Although the level of p27 expression was not correlated with any other possible prognostic markers, such as age, white blood cell count, chromosome abnormalities, and FAB subclasses, patients with high p27 expression had a significantly increased disease-free survival (DFS) (78% vs 19%, P = 0.004). We further examined the expression of cyclin E at the protein level in all 72 AML cases. We observed a statistically significant correlation between a high cyclin E level and a high p27 level (P < 0.005). However, we failed to find any correlation between the rates of cr or dfs and cyclin e expression. The present study reveals that levels of p27 expression can be one of the useful prognostic molecular markers for aml.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Alessandrini A, Chiaur DS, Pagano M . Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation Leukemia 1997 11: 342–345

    Article  CAS  Google Scholar 

  2. Sherr CJ . CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 1999 13: 1501–1512

    Article  CAS  Google Scholar 

  3. Nakayama K, Nakayama K . Cip/Kip cyclin-dependent kinase inhibitors: brakes of the cell cycle engine during development Bioessays 1998 20: 1020–1029

    Article  CAS  Google Scholar 

  4. Chellappan SP, Giordano A, Fisher PB . Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development Curr Top Microbiol Immunol 1998 227: 57–103

    CAS  PubMed  Google Scholar 

  5. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW . p27kipl: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers Am J Pathol 1999 154: 313–323

    Article  CAS  Google Scholar 

  6. Pagano M, Tam SW, Theodoras AM, Beer Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M . Role of the ubiquitin–proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 1995 269: 682–685

    Article  CAS  Google Scholar 

  7. Hengst L, Reed SI . Translational control of p27Kipl accumulation during the cell cycle Science 1996 271: 1861–1864

    Article  CAS  Google Scholar 

  8. Alevizopoulos K, Vlach J, Hennecke S, Amati B . Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins EMBO J 1997 16: 5322–5333

    Article  CAS  Google Scholar 

  9. Clurman BE, Porter P . New insights into the tumor suppression function of P27(kipl) Proc Natl Acad Sci USA 1998 95: 15158–15160

    Article  CAS  Google Scholar 

  10. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI . Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma J Natl Cancer Inst 1998 90: 1284–1291

    Article  CAS  Google Scholar 

  11. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM . Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients Nature Med 1997 3: 222–225

    Article  CAS  Google Scholar 

  12. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M . Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas Nature Med 1997 3: 231–234

    Article  CAS  Google Scholar 

  13. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM . Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer Nature Med 1997 3: 227–230

    Article  CAS  Google Scholar 

  14. Cote RJ, Shi Y, Grodhen S, Feng A, Cordon-Card C, Skinner D, Lieskovosky G . Association of p27kip1 levels with recurrence and survival in patients with stage C prostate carcinoma J Natl Cancer Inst 1998 90: 916–920

    Article  CAS  Google Scholar 

  15. Anayama T, Furihata M, Ishikawa T, Ohtsuki Y, Ogoshi S . Positive correlation between p27Kipl expression and progression of human esophageal squamous cell carcinoma Int J Cancer 1998 79: 439–443

    Article  CAS  Google Scholar 

  16. Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G . Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphoma–prognostic implications Blood 1998 92: 770–777

    CAS  PubMed  Google Scholar 

  17. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum Cymbalista F . Prognostic significance of the cell cycle inhibitor p27Kipl in chronic B-cell lymphocytic leukemia Blood 1998 91: 4694–4700

    CAS  PubMed  Google Scholar 

  18. Won KA, Reed SI . Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E EMBO J 1996 15: 4182–4193

    Article  CAS  Google Scholar 

  19. Keyomarsi K, Herliczek TW . The role of cyclin E in cell proliferation, development and cancer Prog Cell Cycle Res 1997 3: 171–191

    Article  CAS  Google Scholar 

  20. Donnellan R, Chetty R . Cyclin E in human cancers FASEB J 1999 13: 773–780

    Article  CAS  Google Scholar 

  21. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Hatake K, Kuriyama K, Ohmoto E, Saito K, Kanamaru A, Oho H, Ohtake S, Jinnai I, Sakamaki H, Yamada O, Asou N, Takahashi M, Takeyama K, Matsuda S, Ueda R, Ohno R . Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (except for M3) (JALSG-AML92 study) and analysis of prognostic factors Blood 1997 90: (Suppl. 1) 503a

    Google Scholar 

  22. Iida H, Towatari M, Tanimoto M, Morishita Y, Kodera Y, Saito H . Overexpression of cyclin E in acute myelogenous leukemia Blood 1997 90: 3707–3713

    CAS  PubMed  Google Scholar 

  23. Towatari M, May GE, Marais R, Perkins GR, Marshall CJ, Cowley S, Enver T . Regulation of GATA-2 phosphorylation by mitogen-activated protein kinase and interleukin-3 J Biol Chem 1995 270: 4101–4107

    Article  CAS  Google Scholar 

  24. Kaplan G, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  25. Mantel N . Evaluation of statistical data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170

    CAS  Google Scholar 

  26. Cox D . Regression model and life tables JR Stat Assoc 1972 34: 187–220

    Google Scholar 

  27. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, Caputi M, Baldi F, Pagano M, Giordano A . Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer Cancer Res 1997 57: 3381–3385

    CAS  Google Scholar 

  28. Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T . Role of p27Kipl and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer Am J Pathol 1998 153: 505–513

    Article  CAS  Google Scholar 

  29. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM . Reduced expression of the cell cycle inhibitor p27Kipl in non-small cell lung carcinoma: a prognostic factor independent of Ras Cancer Res 1999 59: 684–688

    CAS  PubMed  Google Scholar 

  30. Yasui W, Kudo Y, Semba S, Yokozaki H, Tahara E . Reduced expression of cyclin-dependent kinase inhibitor p27Kipl is associated with advanced stage and invasiveness of gastric carcinomas Jpn J Cancer Res 1997 88: 625–629

    Article  CAS  Google Scholar 

  31. Sgambato A, Zhang YJ, Arber N, Hibshoosh H, Doki Y, Ciaparrone M, Santella RM, Cittadini A, Weinstein IB . Deregulated expression of p27 (Kip1) in human breast cancers Clin Cancer Res 1997 3: 1879–1887

    CAS  PubMed  Google Scholar 

  32. Cayrol C, Ducommun B . Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21 Oncogene 1998 17: 2437–2444

    Article  CAS  Google Scholar 

  33. Fukuchi K, Tomoyasu S, Nakamaki T, Tsuruoka N, Gomi K . DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells Biochim Biophys Acta 1998 1404: 405–411

    Article  CAS  Google Scholar 

  34. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS . Proteasome-dependent regulation of p21WAF1/CIP1 expression Biochem Biophys Res Comm 1996 227: 564–569

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Grants-in-Aid for Cancer Research (No. 9-2) from the Japanese Ministry of Health and Welfare, Tokyo, Japan. The authors thank S Suzuki and C Wakamatsu for their technical assistance. We also think Y Makino for her editorial assistance.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan

    T Yokozawa, M Towatari, H Iida, K Takeya ma, M Tanimoto & H Saito

  2. Department of Infectious Diseases, Nagoya University Hospital, Nagoya, Japan

    H Kiyoi & T Naoe

  3. Department of Hematology, Tokyo Women's Medical College, Tokyo, Japan

    T Motoji

  4. Second Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan

    N Asou

  5. Third Department of Internal Medicine, Dokkyo University School of Medicine, Tochigi, Japan

    K Saito

  6. Department of Medicine, National Sanatorium Minami Okayama Hospital, Okayama, Japan

    M Takeuchi

  7. Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan

    Y Kobayashi

  8. Department of Medicine, Saiseikai Maebashi Hospital, Maebashi, Japan

    S Miyawaki

  9. Japan Red Cross Nagoya First Hospital, Nagoya, Japan

    Y Kodera

  10. Department of Medicine III, Hamamatsu University Medical School, Hamamatsu, Japan

    R Ohno

Authors
  1. T Yokozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Towatari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Takeya ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Tanimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Kiyoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Motoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N Asou
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Takeuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Y Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. S Miyawaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y Kodera
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. R Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. T Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yokozawa, T., Towatari, M., Iida, H. et al. Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia. Leukemia 14, 28–33 (2000). https://doi.org/10.1038/sj.leu.2401640

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401640

Keywords

This article is cited by

Search

Advanced search

Quick links